Summary
The Supreme Court has decided that mifepristone, a key medication used in medical abortions, can still be prescribed through telehealth and delivered by mail for the time being. This decision reverses a recent ruling by the 5th Circuit Court of Appeals, which had attempted to temporarily block doctors from prescribing the medication remotely.
The legal dispute centers on safety protocols known as Risk Evaluation and Mitigation Strategies. Originally, these rules required patients to obtain mifepristone in person, but the Food and Drug Administration lifted those specific restrictions in 2021 to allow remote prescribing. The state of Louisiana is currently challenging this change in court, arguing that allowing doctors to prescribe the drug via telehealth directly undermines the state's strict abortion ban.
It is important to note that the current Supreme Court decision is only a temporary measure. The broader case will continue to move its way through the justice system, meaning the ultimate legality of telehealth distribution for mifepristone remains highly uncertain.
Why it matters.
This ongoing legal battle represents a critical moment for reproductive healthcare access. When the Food and Drug Administration lifted remote prescribing restrictions in 2021, it fundamentally changed how patients could obtain mifepristone, allowing them to consult with doctors online and receive medication at home. A final court ruling that reinstates the old rules would abruptly end this practice, creating significant new hurdles for patients relying on remote care.
Furthermore, Louisiana's lawsuit highlights a major legal conflict between federal medication regulations and state-level healthcare restrictions. Because the Supreme Court has only issued a temporary pause, healthcare providers and patients are left waiting for a final legal resolution that could ultimately reshape the boundaries of telehealth and medical access nationwide.
The story in numbers.
- Year FDA lifted remote prescribing REMS
- 2021
- Circuit Court of Appeals that initially prohibited remote prescribing
- 5th
Follow the evidence.
This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.
